Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers September 23, 2014
Pharmacy Choice - News - U.S. Pharmaceutical Industry - September 23, 2014

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

9/23/14 - Actinium Advisory Board Chairman to Participate in the Cancer Advance Boston: Focus on Innovation Conference at Harvard Medical School
Actinium Pharmaceuticals, Inc., a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Dr. Joseph Jurcic, Chairman of Actinium's Clinical Advisory Board, will participate in the "Combination Therapy: Proposals for Success" panel discussion at the Cancer Advan
9/23/14 - Biopharmaceutical and Vaccine Production Markets to 2018
Dublin- Research and Markets has announced the addition of the "Biopharmaceutical and Vaccine Production Markets" report to their offering. Though biotechnology has created many new therapies and vaccines- including products to treat cancer, diabetes, HIV/AIDS and autoimmune disorders- there are still huge challenges during the final stages of clin
9/23/14 - Catalent and Cingulate Therapeutics Sign Exclusive Agreement for Development of New ADHD Treatments
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it had reached an exclusive development and licensing agreement with privately held biopharmaceutical company, Cingulate Therapeutics, to support the development..
9/23/14 - Collegium Pharmaceutical Announces Issuance of U.S. Patent Covering DETERx(R), an Abuse-Deterrent, Extended-Release, Technology Platform
CANTON, MA/ ACCESSWIRE/ September 23, 2014/ Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that U.S. Collegium recently announced positive Phase 3 study results for Oxycodone DETERx (R) and expects to submit an NDA in the fourth quarter of 2014. The product has been designated Fast Track Status by the FDA.
9/23/14 - Collegium Pharmaceutical Announces Issuance of U.S. Patent Covering DETERx, an Abuse-Deterrent, Extended-Release, Technology Platform
CANTON, MA, United States, via ETELIGIS INC., 09/23/2014 Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that U.S. Collegium recently announced positive Phase 3 study results for Oxycodone DETERx and expects to submit an NDA in the fourth quarter of 2014. The product has been designated Fast Track Status by the
9/23/14 - Credence MedSystems Introduces the Companion Safety Syringe System
Credence MedSystems, Inc. announced today the launch of the Credence Companion Safety Syringe System at two upcoming conferences focused on drug delivery solutions. The Companion results from the Credence team s intense desire to improve patient care by understanding and addressing the needs of both the end-user performing the injection as well
9/23/14 - Development and Regulation of Abuse-Deterrent Formulations of Opioid Medications; Public Meeting
The meeting will focus on scientific and technical issues related to the development and in vitro assessment of these products, as well as FDA's approach towards assessing the benefits and risks of all opioid medications, including those with abuse-deterrent properties. FDA is seeking input on these issues from all stakeholders, including patients,
9/23/14 - DGAP-News: Press Release: 4SC's partner Yakult Honsha completes Phase I part of clinical study with resminostat in Asian HCC patients and starts randomised Phase II part
DGAP-News: 4 SC AG/ Key word: Miscellaneous Press Release: 4 SC's partner Yakult Honsha completes Phase I part of clinical study with resminostat in Asian HCC patients and starts randomised Phase II part 23.09. 2014/ 07:30- Press Release 4 SC's partner Yakult Honsha completes Phase
9/23/14 - DGAP-News: Press Release: 4SC's partner Yakult Honsha completes Phase I part of clinical study with resminostat in Asian HCC patients and starts randomised Phase II part (english)
Press Release: 4 SC's partner Yakult Honsha completes Phase I part of clinical study with resminostat in Asian HCC patients and starts randomised Phase II part DGAP-News: 4 SC AG/ Key word: Miscellaneous Press Release: 4 SC's partner Yakult Honsha completes Phase I part of clinical study with resminostat in Asian HCC patients and starts randomised
9/23/14 - EOS imaging Secures FDA Clearance for sterEOS 3D and sterEOS 1.6 [Health & Beauty Close - Up]
EOS imaging reported that its next-generation sterEOS 3 D imaging software, sterEOS 1.6, has received 510 clearance from the U.S. Food and Drug Administration. Concurrent with the FDA clearance, the benefits of EOS and its software sterEOS were highlighted at the 49th Annual Meeting of the Scoliosis Research Society in Anchorage, Alaska and during
9/23/14 - FDA Approves Stendra sNDA [Professional Services Close - Up]
Vivus and Auxilium Pharmaceuticals reported that the U.S. Food and Drug Administration has approved a supplemental new drug application for Stendra. According to a media release, Stendra is now the only FDA- approved erectile dysfunction medication indicated to be taken as early as approximately 15 minutes before sexual activity. "Stendra is the f
9/23/14 - First-Ever Conception Assistance Device FDA-Cleared for Home Use Launches U.S. OTC Sales The Stork OTC Delivers Hope to Millions Struggling to Conceive A Child
Rinovum Women's Health announced today that The Stork OTCthe only home-use conception assistance device on the market cleared by the FDA for over-the-counter salesis available without a prescription in stores and online at http://www.storkotc.com. It is the only FDA- cleared product that provides consumers a safe, easy way to perform cervica
9/23/14 - Ignyta to Take Part in Precision Medicine Panel Discussions [Health & Beauty Close - Up]
Dr. Lim will participate in a panel discussion on the topic of "Novel Science Developments: Precision Medicine," moderated by Bill Rastetter, Ph.D., Former Executive Chairman of Biogen Idec and Former Chairman and CEO of Idec Pharma, at the Leerink Healthcare Leadership Summit on September 18, in Napa, California. Dr. Lim will also be part of a pan
9/23/14 - Ivantis Raises Additional $25 MM, Increasing Series B to $71 MM
Ivantis, developer of the novel Hydrus Microstent device designed to lower eye pressure for glaucoma patients, announced today that it secured an additional $25 MM in its Series B financing. The latest close in the Series B includes new investor Foresite Capital, plus returning investors New Enterprise Associates, Delphi Ventures, Ascension Venture
9/23/14 - Mystic Pharmaceuticals Assigned Patent
ALEXANDRIA, Va., Sept. 23 Mystic Pharmaceuticals, Austin, Texas, has been assigned a patent developed by Christopher D. Shay, Horseshoe Bay, Texas, and Timothy R. Sullivan, Austin, Texas, for "medical devices for dispensing powders." The patent application was filed on March 29, 2012. Written by Sudarshan Harpal; edited by Jaya Anand.
9/23/14 - New Clinical Trials and Studies Findings from Moffitt Cancer Center Reported (Studying cancer treatment in the elderly patient population) (Studying...
By a News Reporter-Staff News Editor at Cancer Weekly A new study on Clinical Research is now available. Our news editors obtained a quote from the research from Moffitt Cancer Center, "The literature relating to cancer treatment in the older patient population was reviewed. The news editors report that additional information may be obtained by c
9/23/14 - Noxxon Pharma Names Don Munoz as CFO [Health & Beauty Close - Up]
Noxxon Pharma has appointed Don Munoz to the newly created position of Chief Financial Officer. According to a release, before joining Noxxon Pharma, Don was Head of Investment Banking at Summer Street Research Partners, an investment banking and institutional securities firm focused exclusively on healthcare. He also spent approximately 10 years i
9/23/14 - Patent Issued for Compounds for Treating Proliferative Disorders
By a News Reporter-Staff News Editor at Cancer Weekly From Alexandria, Virginia, NewsRx journalists report that a patent by the inventors Wang, Shudong; Chahrour, Osama; Lu, Tiangong; Hu, Anran, filed on June 21, 2011, was published online on September 9, 2014. The patent's assignee for patent number 8829003 is Changzhou Le Sun Pharmaceuticals Li
9/23/14 - Patent Issued for Tobacco Alkaloid Releasing Chewing Gum
By a News Reporter-Staff News Editor at Life Science Weekly Fertin Pharma A/S has been issued patent number 8828361, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors. The patent's inventor is Andersen, Carsten. This patent was filed on July 23, 2013 and was published online on September 9, 2014.
9/23/14 - Personalized Care from Disease Detection through Treatment Assessment: GE Healthcare Announces FDA Clearance of Discovery IQ
Release date- 22092014- WAUKESHA, Wis.- GE Healthcare today announced U.S. FDA 510 clearance of its Discovery* IQ PET/CT system, enabling both outstanding image quality and intelligent quantitation to help physicians deliver the best possible patient outcomes. 'By 2020, it's estimated that 50% of people will develop cancer at some point in their li
9/23/14 - PM360 Magazine Announces Winners of 2014 Trailblazer Awards
The Pharmaceutical or Biotech Company of the Year went to Eli Lilly and Company, and Steven Millerman, CEO of Prime Access, was named the Trailblazer Marketer of the Year for his exceptional work revolutionizing multi-cultural healthcare communications. This year's PM360 Lifetime Achievement Award went to that Ron Pantello, Founder of Lally, McFarl
9/23/14 - Provectus Intralesional Pv-10 and Co-Inhibitory Blockade Data to Be Presented at SITC 29th Annual Meeting
Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that a team of researchers led by Shari Pilon-Thomas, PhD from the Moffitt Cancer Center will present data at the Society for Immunotherapy of Cancer 29 th Annual Meeting with an abstract titled Efficacy of Intralesional...
9/23/14 - Reports: Allergan In Advanced Talks To Acquire Salix Pharmaceuticals
OTTAWA- Botox maker Allergan Inc. is in advanced talks to buy Salix Pharmaceuticals Ltd. in order to fend off a $53 billion hostile bid from Canada- based Valeant Pharmaceuticals Inc., according to media reports on Monday. Irvine, California- based Allergan's acquisition of Salix would likely halt a hostile bid for the company from Valeant Pharma a
9/23/14 - Titan Pharmaceuticals Announces Enrollment Reaches Halfway Mark in Phase 3 Study of Probuphine for Opioid Dependence
Titan Pharmaceuticals, Inc. today announced that patient enrollment in the Phase 3 study of Probuphine , the company's investigational subdermal implant for the maintenance treatment of opioid dependence, has reached the halfway mark. Titan's partner, Braeburn Pharmaceuticals, is sponsoring the study and expects it to be fully enrolled before the
9/22/14 - "Compositions and Methods for Reducing a Fatty Acid Desaturation Index in a Subject in Need Thereof" in Patent Application Approval Process
By a News Reporter-Staff News Editor at Cardiovascular Week A patent application by the inventors Braeckman, Rene; Stirtan, William; Soni, Paresh, filed on February 28, 2014, was made available online on September 11, 2014, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

The Diversion of Controlled Substances and the Law
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comPharmacyPages.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415